(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 November 2011 (03.11.2011)

PCT

(10) International Publication Number
WO 2011/134084 A1

(51) International Patent Classification:
*A61K 47/48* (2006.01) *A61P 19/08* (2006.01)
*A61K 31/7088* (2006.01) *C12N 9/16* (2006.01)
*A61K 38/17* (2006.01) *C12N 15/55* (2006.01)
*A61K 38/46* (2006.01) *C12N 15/867* (2006.01)
*A61K 48/00* (2006.01)

(21) International Application Number:
PCT/CA2011/050258

(22) International Filing Date:
29 April 2011 (29.04.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/329,877 30 April 2010 (30.04.2010) US

(71) Applicant *(for all designated States except US)*: **ENOBIA PHARMA INC.** [CA/CA]; 2901, Rachel Street East, Suite 23, Montreal, Quebec H1W 4A4 (CA).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **CRINE, Philippe** [CA/CA]; 28 Avenue Claude-Champagne, Outremont, Quebec H2V 2X1 (CA). **LEONARD, Pierre** [CA/CA]; 12364 Notre-Dame des Anges street, Montreal, Quebec H4J 2C4 (CA).

(74) Agent: **GOUDREAU GAGE DUBUC**; 2000 McGill College, Suite 2200, Montreal, Quebec H3A 3H3 (CA).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17**:


— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

**Published**:

— *with international search report (Art. 21(3))*

(54) Title: METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MATRIX MINERALIZATION DISORDERS

Figure 1




(57) Abstract: The present invention provides methods, compositions, and kits for the treatment of matrix mineralization disorders such as hypophosphatasia. In particular, the present invention provides polypeptides having a soluble alkaline phosphatase fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to patients, e.g., subcutaneously, to treat hypophosphatasia using enzyme replacement therapy. The invention also features nucleic acids encoding such polypeptides and the use of the nucleic acids for treating matrix mineralization disorders.

WO 2011/134084 A1